On October 29, Genor Biopharma Co. Ltd. announced a strategic cooperation with Hutchison Whampoa Pharmaceuticals (Shanghai) Co., Ltd., an innovative drug research and development platform under Hutchison China Pharmaceutical Technology Co., Ltd., to study the combination usage of Genor ‘s genolimzumab antibody (GB226) and Whampoa’s Furazolinib for the treatment of advanced solid tumors.
The two companies will first explore and study the effects of combining genolimzumab and fruquintinib on a variety of solid tumor types. Phase Ib studies are expected to enter the step of recruiting patients in China by the end of 2018, to determine safety and recommended dosing regimens. Based on Phase 1b data, it will be decided whether to conduct a phase III clinical safety and efficacy study.
Genolimzumab (GB226) is a humanized IgG4 monoclonal antibody targeting the immune cell PD-1. It was originally developed by CBT Pharmaceuticals Inc. of the United States and was authorized in September 2016 for Genor Bio to develop in the Chinese market. CBT Retained rights outside of China. Genor Bio was approved for the first clinical trial in China in December 2016 and is currently in Phase II clinical trials for the treatment of a variety of neoplasms, including non-Hodgkin’s lymphoma.
Fruquintinib is a vascular endothelial growth factor receptor (VEGFR) inhibitor approved by the National Drug Administration (NMPA) for oral treatment of metastatic colorectal cancer (mCRC) in September. The high kinase selectivity of this drug has been shown to reduce off-target toxicity, meaning that it has great potential for use in combination with other therapeutic agents.